Novel Expanding Renal Cell Carcinoma Biomarkers

  • Francesco Claps
  • Maria Carmen Mir
Keywords: renal cell carcinoma, biomarker, diagnosis, prognosis, survival


Identification of reliable molecular biomarkers that can complement clinical practice represents a fascinating challenge in any cancer field. Renal tumors are usually asymptomatic and incidentally identified during imaging studies due to unrelated causes. However, in 25-30% of patients the first diagnosis is accompanied by symptoms and associated with distant metastasis. Thus, early diagnosis may improve the disease progression also avoiding side effects of inadequate treatments. Moreover, the ability to categorize patients' risk of recurrence after radical treatment, or even predict benefit from a target therapy represent a compelling challenge. Here we reviewed the current state-of-the-art on RCC biomarkers, particularly focusing on the new approaches of genomics, liquid biopsy, proteomics and metabolomics.

How to Cite
Claps, F., & Mir, M. C. (2021). Novel Expanding Renal Cell Carcinoma Biomarkers. Société Internationale d’Urologie Journal, 2(1), 32-42. Retrieved from
Molecular Biomarkers in Urologic Oncology